Get the Stockscreener App
2.30
3.14%
0.07
After Hours:
2.30
Ac Immune Sa stock is traded at $2.30, with a volume of 130.80K.
It is up +3.14% in the last 24 hours and down -10.16% over the past month.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$2.23
Open:
$2.23
24h Volume:
130.80K
Relative Volume:
0.48
Market Cap:
$234.08M
Revenue:
$4.60M
Net Income/Loss:
$-82.31M
P/E Ratio:
-2.8042
EPS:
-0.8202
Net Cash Flow:
$-87.79M
1W Performance:
+2.22%
1M Performance:
-10.16%
6M Performance:
-35.03%
1Y Performance:
-5.35%
1-Day Range:
$2.19
$2.34
1-Week Range:
$2.16
$2.34
52-Week Range:
$2.03
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.30 | 226.96M | 4.60M | -82.31M | -87.79M | -0.8202 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
AC Immune SA (ACIU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AC Immune SA (ACIU) Cash Flow - TradingKey
TradingKey - TradingKey
AC Immune SA (ACIU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ACIU|AC Immune SA|Price:2.230|Chg%:-0.010 - TradingKey
AC Immune SA Revenue Breakdown – TRADEGATE:IMR - TradingView
AC Immune SA (ACIU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AC Immune Q1 2026 Earnings: Narrower Loss and Positive Surprise Highlight ProgressProduct Revenue Analysis - dars.gov.et
AC Immune (ACIU) Posts Modest Gain, Holds Above Key SupportDay Trade Opportunities - dars.gov.et
AC Immune Q1 2026 Earnings: Narrowed Loss Per Share Exceeds Expectations, Stock RisesAnalyst Coverage Count - dars.gov.et
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - The Manila Times
AC Immune brings three neurodegeneration studies to AAIC 2026 - Stock Titan
AC Immune: Holding Into A Make-Or-Break H2 2026 Readout (NASDAQ:ACIU) - Seeking Alpha
H.C. Wainwright reiterates AC Immune stock rating on trial data By Investing.com - Investing.com Australia
H.C. Wainwright reiterates AC Immune stock rating on trial data - Investing.com
AC Immune (ACIU) Slides 6.93% as Biotech Pressure Mounts – Key Support in FocusCollar Trade - dars.gov.et
Price to earnings forward of AC Immune SA – DUS:IMR - TradingView
Price to sales forward of AC Immune SA – NASDAQ:ACIU - TradingView
AC Immune Unveils 12-Month Interim Data from ACI-24 Alzheimer’s Trial and Expands Takeda-Backed Program - TipRanks
Takeda-backed AC Immune (NASDAQ: ACIU) reports ACI-24 Alzheimer’s trial update - Stock Titan
ACIU: Promising Interim Results from AC Immune's Alzheimer's Stu - GuruFocus
AC Immune reports interim trial data for Alzheimer’s drug ACI-24 - Investing.com Australia
AC Immune Reports Interim 12-Month ABATE Data for ACI-24 in Prodromal Alzheimer’s Disease - Quiver Quantitative
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease - GlobeNewswire
AC Immune Q1 2026 Earnings: Narrowing Losses and Positive Pipeline MomentumProfit Cycle Analysis - dars.gov.et
Enterprise value to EBITDA forward of AC Immune SA – NASDAQ:ACIU - TradingView
Enterprise value to EBIT forward of AC Immune SA – NASDAQ:ACIU - TradingView
Price to book forward of AC Immune SA – NASDAQ:ACIU - TradingView
Enterprise value to revenue forward of AC Immune SA – NASDAQ:ACIU - TradingView
Price to earnings forward of AC Immune SA – NASDAQ:ACIU - TradingView
ACIU Forecast — Price Target — Prediction for 2027 - TradingView
AC Immune Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pipeline Progress ContinuesTax Rate Impact - dars.gov.et
AC Immune SA (ACIU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ACIU Q1 2026 Earnings: Narrower-Than-Expected Loss Sparks Modest Stock GainGuidance Downgrade Alert - dars.gov.et
AC Immune SA (ACIU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACIU Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in Alzheimer’s PipelineFree Cash Flow Trends - DonanımHaber
AC Immune SA (ACIU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AC Immune SA (ACIU) Institutional Confidence - TradingKey
AC Immune SA (ACIU) Valuation: PE, PB & Fair Value Analysis - TradingKey
AC Immune SA (ACIU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ACIU Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
June 2026 Penny Stocks To Watch For Potential Growth - simplywall.st
AC Immune (ACIU) director receives restricted share units and options grant - Stock Titan
AC Immune (ACIU) director receives new RSU and stock option grants - Stock Titan
AC Immune (ACIU) interim CEO Martin Zuegel granted RSUs and stock options - Stock Titan
AC Immune (ACIU) grants RSUs and stock options to director Buetler - Stock Titan
[Form 4] AC Immune SA Insider Trading Activity - Stock Titan
AC Immune Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Investor ResponseDividend Increase Stocks - newsline.com
INDV Stock: What Sublocade Growth Signals for 2026 - TradingView
ACIU SEC FilingsAC Immune 10-K, 10-Q, 8-K Forms - Stock Titan
AC Immune Shareholders Back Capital Band, Governance Slate and Pay Caps at June 11 AGM - TipRanks
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):